[A novel therapeutic vaccine approach against RANKL that prevents pathological bone destruction].
The vaccination method is used to induce antibody response against disease-related proteins by immunization with modified pathological antigen as preventive therapy to acquire disease resistance. A RANKL vaccine was developed by modifying the soluble TNF-like domain of murine RANKL to incorporate a promiscuous Th epitope. Immunization with RANKL vaccine prevented pathological bone resorption in arthritic mice or ovariactomized mice.
Tanaka
Sakae
S
Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo.
D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy*; D002352:Carrier Proteins / Q000276:immunology*; D007114:Immunization; D008562:Membrane Glycoproteins / Q000276:immunology*; D051379:Mice; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D014612:Vaccines / Q000627:therapeutic use*
D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505687:Tnfrsf11a protein, mouse; C505689:Tnfsf11 protein, mouse; D014612:Vaccines